REFERENCES

1. Fine-Edelstein JS, Wolf PA, O’Leary DH, Poehlman H, Belanger AJ, et al. Precursors of extracranial carotid atherosclerosis in the Framingham study. Neurology 1994;44:1046-50.

2. Rockman CB, Hoang H, Guo Y, Maldonado TS, Jacobowitz GR, et al. The prevalence of carotid artery stenosis varies significantly by race. J Vasc Surg 2013;57:327-37.

3. The Intercollegiate Working Party for Stroke. National clinical guidelines for stroke. 2th ed. London: Royal College of Physicians; 2004.

4. Markl M, Wegent F, Zech T, Bauer S, Strecker C, et al. In vivo wall shear stress distribution in the carotid artery: effect of bifurcation geometry, internal carotid artery stenosis, and recanalization therapy. Circ Cardiovasc Imaging 2010;3:647-55.

5. Spence JD. Asymptomatic carotid stenosis. Circulation 2013;127:739-42.

6. Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke 2010;41:e11-7.

7. Raman G, Moorthy D, Hadar N, Dahabreh IJ, O’Donnell TF, et al. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Ann Intern Med 2013;158:676-85.

8. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-50.

9. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.

10. Hosomi N, Kitagawa K, Nagai Y, Nakagawa Y, Aoki S, et al. Desirable low-density lipoprotein cholesterol levels for preventing stroke recurrence: a post hoc analysis of the J-STARS study (Japan Statin Treatment Against Recurrent Stroke). Stroke 2018;49:865-71.

11. Prasad K. Do statins have a role in reduction/prevention of post- PCI restenosis? Cardiovasc Ther 2013;31:12-26.

12. Crouse JR, Byington RP, Bond MG, Espeland MA, Sprinkle JW, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. Control Clin Trials 1992;13:495-506.

13. Espeland MA, O’Leary DH, Terry JG, Morgan T, Evans G, et al. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005;6:3.

14. Bedi US, Singh M, Singh PP, Bhuriya R, Bahekar A, et al. Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal--medial thickness: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2010;15:268-73.

15. Koga M, Toyoda K, Minematsu K, Yasaka M, Nagai Y, et al. Long-term effect of pravastatin on carotid intima-media complex thickness: the J-STARS echo study (Japan Statin Treatment Against Recurrent Stroke). Stroke 2018;49:107-13.

16. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002;106:2884-7.

17. Ainsworth CD, Blake CC, Tamayo A, Beletsky V, Fenster A, et al. 3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies. Stroke 2005;36:1904-9.

18. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009;53:2039-50.

19. Mujaj B, Bos D, Selwaness M, Leening MJG, Kavousi M, et al. Statin use is associated with carotid plaque composition: the Rotterdam study. Int J Cardiol 2018;260:213-8.

20. Prasad K. Pathophysiology of atherosclerosis. In: Chang JB, Olsen ER, Prasad K, Sumpio BE, editors. Textbook of Angiology. New Yor: Springer Verlag; 2000. pp. 85-105.

21. Prasad K. Pathophysiology and medical treatment of carotid artery stenosis. Int J Angiol 2015;24:158-72.

22. Orekhov AN, Ivanova EA. Introduction of the special issue “Atherosclerosis and Related Diseases”. Vessel Plus 2017;1:163-5.

23. Schaffner T, Taylor K, Bartucci EJ, Fischer-Dzoga K, Beeson JH, et al. Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am J Pathol 1980;100:57-80.

24. Hundal RS, Salh BS, Schrader JW, Gómez-Muñoz A, Duronio V, et al. Oxidized low density lipoprotein inhibits macrophage apoptosis through activation of the PI 3-kinase/PKB pathway. J Lipid Res 2001;42:1483-91.

25. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.

26. Moreno PR, Purushothaman KR, Zias E, Sanz J, Fuster V. Neovascularization in human atherosclerosis. Curr Mol Med 2006;6:457-77.

27. Carr S, Farb A, Pearce WH, Virmani R, Yao JS. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996;23:755-65.

28. Morgan AR, Rerkasem K, Gallagher PJ, Zhang B, Morris GE, et al. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke 2004;35:1310-5.

29. Montecucco F, Di Marzo V, da Silva RF, Vuilleumier N, Capettini L, et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012;33:846-56.

30. Rao VH, Rai V, Stoupa S, Subramanian S, Agrawal DK. Tumor necrosis factor-α regulates triggering receptor expressed on myeloid cells-1-dependent matrix metalloproteinases in the carotid plaques of symptomatic patients with carotid stenosis. Atherosclerosis 2016;248:160-9.

31. Fang Y, Mohler ER 3rd, Hsieh E, Osman H, Hashemi SM, et al. Hypercholesterolemia suppresses inwardly rectifying K+ channels in aortic endothelium in vitro and in vivo. Circ Res 2006;98:1064-71.

32. Morikage N, Kishi H, Sato M, Guo F, Shirao S, et al. Cholesterol primes vascular smooth muscle to induce Ca2 sensitization mediated by a sphingosylphosphorylcholine-Rho-kinase pathway: possible role for membrane raft. Circ Res 2006;99:299-306.

33. Amiya E. Interaction of hyperlipidemia and reactive oxygen species: insights from the lipid-raft platform. World J Cardiol 2016;8:689-94.

34. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 2002;277:38503-16.

35. Zhang Q, Malik P, Pandey D, Gupta S, Jagnandan D, et al. Paradoxical activation of endothelial nitric oxide synthase by NADPH oxidase. Arterioscler Thromb Vasc Biol 2008;28:1627-33.

36. Borén J, Taskinen MR, Olofsson SO, Levin M. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med 2013;274:25-40.

37. Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009;50:204-13.

38. Welty FK. How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis? Curr Cardiol Rep 2013;15:400.

39. Botham KM, Moore EH, De Pascale C, Bejta F. The induction of macrophage foam cell formation by chylomicron remnants. Biochem Soc Trans 2007;35:454-8.

40. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61.

41. Harangi M, Szentpéteri A, Nádró B, Lőrincz H, Seres I, et al. HDL subfraction distribution and HDL function in untreated dyslipidemic patients. Vessel Plus 2017;1:166-73.

42. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004;109:III8-14.

43. Peshavariya H, Dusting GJ, Di Bartolo B, Rye KA, Barter PJ, et al. Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radic Res 2009;43:772-82.

44. Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997;238:61-5.

45. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004;318:680-3.

46. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991;88:2039-46.

47. Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 1994;14:1775-83.

48. Nofer JR, Walter M, Kehrel B, Wierwille S, Tepel M, et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998;18:861-9.

49. Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2009;40:382-8.

50. Kim YS, Sung HJ, Son SJ, Lim J, Kang YW, et al. Triglyceride (TG) down-regulates expression of MCP-1 and CCR2 in PMA-derived THP-1 macrophages. Genes Genomics 2013;35:125-30.

51. Labreuche J, Deplanque D, Touboul PJ, Bruckert E, Amarenco P. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis. Atherosclerosis 2010;212:9-15.

52. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008;196:489-96.

53. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010;21:312-8.

54. Tiozzo E, Gardener H, Hudson BI, Dong C, Della-Morte D, et al. High-density lipoprotein subfractions and carotid plaque: the Northern Manhattan study. Atherosclerosis 2014;237:163-8.

55. Chei CL, Yamagishi K, Kitamura A, Kiyama M, Imano H, et al. High-density lipoprotein subclasses and risk of stroke and its subtypes in Japanese population: the circulatory risk in communities study. Stroke 2013;44:327-33.

56. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 2013;44:1833-9.

57. Xie L, Wu W, Chen J, Tu J, Zhou J, et al. Cholesterol levels and hemorrhagic stroke risk in East Asian versus Non-East Asian populations: a systematic review and meta-analysis. Neurologist 2017;22:107-15.

58. Mathiesen EB, Joakimsen O, Bønaa KH. Prevalence of and risk factors associated with carotid artery stenosis: the Tromsø study. Cerebrovasc Dis 2001;12:44-51.

59. Raitakari OT, Juonala M, Kähönen M, Taittonen L, Laitinen T, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young Finns study. JAMA 2003;290:2277-83.

60. Vouillarmet J, Helfre M, Maucort-Boulch D, Riche B, Thivolet C, et al. Carotid atherosclerosis progression and cerebrovascular events in patients with diabetes. J Diabetes Complications 2016;30:638-43.

61. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008;299:1678-89.

62. Kitagami M, Yasuda R, Toma N, Shiba M, Nampei M, et al. Impact of hypertriglyceridemia on carotid stenosis progression under normal low-density lipoprotein cholesterol levels. J Stroke Cerebrovasc Dis 2017;26:1793-800.

63. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002;942:23-30.

64. Cheng ZJ, Dai TM, Shen YY, He JL, Li J, et al. Atorvastatin pretreatment attenuates ischemic brain edema by suppressing aquaporin 4. J Stroke Cerebrovasc Dis 2018;27:3247-55.

65. Zhu MX, Lu C, Xia CM, Qiao ZW, Zhu DN. Simvastatin pretreatment protects cerebrum from neuronal injury by decreasing the expressions of phosphor-CaMK II and AQP4 in ischemic stroke rats. J Mol Neurosci 2014;54:591-601.

66. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation 2011;124:e54-130.

67. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, doubleblind trial. Lancet 2001;357:577-81.

68. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, et al. Effects of aggressive versus conventional lipid-lowering by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005;46:106-12.

69. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008;155:584.

70. Lee JM, Wiesmann F, Shirodaria C, Leeson P, Petersen SE, et al. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis 2008;197:951-8.

71. Lenglet S, Quercioli A, Fabre M, Galan K, Pelli G, et al. Statin treatment is associated with reduction in serum levels of receptor activator of NF-kB ligand and neutrophil activation in patients with severe carotid stenosis. Mediators Inflamm 2014;2014:720987.

72. McGirt MJ, Perler BA, Brooke BS, Woodworth GF, Coon A, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005;42:829-36.

73. Tanemura H, Maeda M, Ichikawa N, Miura Y, Umeda Y, et al. High-risk plaque for carotid artery stenting evaluated with 3-dimensional T1-weighted gradient echo sequence. Stroke 2013;44:105-10.

74. Texakalidis P, Giannopoulos S, Jonnalagadda AK, Chitale RV, Jabbour P, et al. Preoperative use of statins in carotid artery stenting: a systematic review and meta-analysis. J Endovasc Ther 2018;25:624-31.

75. De Caterina R, Scarano M, Marfisi R, Lucisano G, Palma F, et al. Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll of Cardiol 2010;55:198-211.

76. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010;121:110-22.

77. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, et al. The ARBITER 6-HALTS trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721-6.

78. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013;61:440-6.

79. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Circulation 2001;103:2828-33.

80. Jun M, Foote C, Lv J, Neal B, Patel A, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84.

81. Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol 2018;12:173-84.

82. Calvo MJ, Martínez MS, Torres W, Chávez-Castillo M, Luzardo E, et al. Omega-3 polyunsaturated fatty acids and cardiovascular health: a molecular view into structure and function. Vessel Plus 2017;1:116-28.

83. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361:477-85.

84. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010;212:252-9.

85. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.

86. Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial). Circulation 2017;136:2440-50.

87. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.

88. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.

89. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017;376:1933-42.

90. HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017;377:1217-27.

91. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014;11:563-75.

92. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163:40-51.

93. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99.

94. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;253:281-344.

95. Iacoviello L, Bonaccio M, Cairella G, Catani MV, Costanzo S, et al. Diet and primary prevention of stroke: systematic review and dietary recommendations by the ad hoc Working Group of the Italian Society of Human Nutrition. Nutr Metab Cardiovasc Dis 2018;28:309-34.

96. Lee IM, Hennekens CH, Berger K, Buring JE, Manson JE. Exercise and risk of stroke in male physicians. Stroke 1999;30:1-6.

Vessel Plus
ISSN 2574-1209 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/